keyword
MENU ▼
Read by QxMD icon Read
search

SHP2 AND NSCLC

keyword
https://read.qxmd.com/read/30806814/emerging-targeted-therapies-for-the-treatment-of-non-small-cell-lung-cancer
#1
REVIEW
Patrick R Halliday, Collin M Blakely, Trever G Bivona
PURPOSE OF REVIEW: Lung cancer remains the leading cause of cancer-related mortality worldwide. Genetic and molecular profiling of non-small cell lung cancer (NSCLC) has led to the discovery of actionable oncogenic driver alterations, which has revolutionized treatment for this disease. This review will move beyond traditional mutational drivers such as EGFR and ALK and will instead focus on emerging targets and the efficacy of new precision therapies. RECENT FINDINGS: Here, we discuss both established and emerging targeted therapy approaches, as well as ongoing challenges for the treatment of NSCLC patients harboring oncogenic alterations of the following types-gene fusions (ROS1, RET, NTRK), receptor tyrosine kinases (MET amplification and exon 14 mutations and EGFR/HER2 exon 20 insertion mutations), and MAPK signaling (SHP2 and altered BRAF and NF1)...
February 26, 2019: Current Oncology Reports
https://read.qxmd.com/read/30685130/association-of-nuclear-localization-of-shp2-and-yap1-with-unfavorable-prognosis-in-non-small-cell-lung-cancer
#2
Ming-Jenn Chen, Yao-Chen Wang, De-Wei Wu, Chi-Yi Chen, Huei Lee
Src homology region 2 (SH2)-containing protein tyrosine phosphatase 2 (SHP2) is ubiquitously expressed in cytoplasmic localization, which in turn confers tumor malignancy and poor prognosis in various human cancers. YAP1 interacts with SHP2 to promote translocation of SHP2 to nucleus, which consequently promotes Wnt target activation. However, the oncogenic role of the nuclear localization of SHP2 in human cancers remains unclear. We hypothesized that nuclear SHP2 localization, in combination with nuclear YAP1 expression, could be associated with poor overall survival (OS) and relapse free survival (RFS) due to an increase in cyclin D1 and c-Myc mRNA expression following activation of Wnt/ß-catenin signaling...
January 18, 2019: Pathology, Research and Practice
https://read.qxmd.com/read/30473379/integrin-linked-kinase-ilk-and-src-homology-2-domain-containing-phosphatase-2-shp2-novel-targets-in-egfr-mutation-positive-non-small-cell-lung-cancer-nsclc
#3
Niki Karachaliou, Andres Felipe Cardona, Jillian Wilhelmina Paulina Bracht, Erika Aldeguer, Ana Drozdowskyj, Manuel Fernandez-Bruno, Imane Chaib, Jordi Berenguer, Mariacarmela Santarpia, Masaoki Ito, Jordi Codony-Servat, Rafael Rosell
BACKGROUND: The activation of multiple signaling pathways jeopardizes the clinical efficacy of EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutation positive non-small cell lung cancer (NSCLC). Integrin-linked kinase (ILK) regulates the interactions between tumor cells and extracellular environment to activate signaling pathways and promote cell proliferation, migration, and epithelial-mesenchymal transition. Src homology 2 domain-containing phosphatase 2 (SHP2) is essential for receptor tyrosine kinase signaling and mitogen-activated protein kinase (MAPK) pathway activation...
November 22, 2018: EBioMedicine
https://read.qxmd.com/read/29808006/shp2-is-required-for-growth-of-kras-mutant-non-small-cell-lung-cancer-in-vivo
#4
Sara Mainardi, Antonio Mulero-Sánchez, Anirudh Prahallad, Giovanni Germano, Astrid Bosma, Paul Krimpenfort, Cor Lieftink, Jeffrey D Steinberg, Niels de Wit, Samuel Gonçalves-Ribeiro, Ernest Nadal, Alberto Bardelli, Alberto Villanueva, Rene Bernards
RAS mutations are frequent in human cancer, especially in pancreatic, colorectal and non-small-cell lung cancers (NSCLCs)1-3 . Inhibition of the RAS oncoproteins has proven difficult4 , and attempts to target downstream effectors5-7 have been hampered by the activation of compensatory resistance mechanisms8 . It is also well established that KRAS-mutant tumors are insensitive to inhibition of upstream growth factor receptor signaling. Thus, epidermal growth factor receptor antibody therapy is only effective in KRAS wild-type colon cancers9,10 ...
July 2018: Nature Medicine
https://read.qxmd.com/read/29523509/shp2-inhibition-may-resensitize-nsclc-tumors-to-alk-inhibitors
#5
(no author information available yet)
Targeting SHP2 suppresses ALK inhibitor resistance caused by tyrosine kinase reactivation.
May 2018: Cancer Discovery
https://read.qxmd.com/read/29207630/shp2-regulates-migratory-behavior-and-response-to-egfr-tkis-through-erk1-2-pathway-activation-in-non-small-cell-lung-cancer-cells
#6
Yu-Jing Sun, Zhong-Ling Zhuo, Hai-Peng Xian, Ke-Zhong Chen, Fan Yang, Xiao-Tao Zhao
In the clinical treatment of lung cancer, therapy failure is mainly caused by cancer metastasis and drug resistance. Here, we investigated whether the tyrosine phosphatase Shp2 is involved in the development of metastasis and drug resistance in non-small cell lung cancer (NSCLC). Shp2 was overexpressed in a subset of lung cancer tissues, and Shp2 knockdown in lung cancer cells inhibited cell proliferation and migration, downregulated c-Myc and fibronectin expression, and upregulated E-cadherin expression. In H1975 cells, which carry double mutations (L858R + T790M) in epidermal growth factor receptor (EGFR) that confers resistance toward the tyrosine kinase inhibitor gefitinib, Shp2 knockdown increased cellular sensitivity to gefitinib; conversely, in H292 cells, which express wild-type EGFR and are sensitive to gefitinib, Shp2 overexpression increased cellular resistance to gefitinib...
October 31, 2017: Oncotarget
https://read.qxmd.com/read/27530552/targeted-nanoconjugate-co-delivering-sirna-and-tyrosine-kinase-inhibitor-to-kras-mutant-nsclc-dissociates-gab1-shp2-post-oncogene-knockdown
#7
R Srikar, Dhananjay Suresh, Ajit Zambre, Kristen Taylor, Sarah Chapman, Matthew Leevy, Anandhi Upendran, Raghuraman Kannan
A tri-block nanoparticle (TBN) comprising of an enzymatically cleavable porous gelatin nanocore encapsulated with gefitinib (tyrosine kinase inhibitor (TKI)) and surface functionalized with cetuximab-siRNA conjugate has been synthesized. Targeted delivery of siRNA to undruggable KRAS mutated non-small cell lung cancer cells would sensitize the cells to TKI drugs and offers an efficient therapy for treating cancer; however, efficient delivery of siRNA and releasing it in cytoplasm remains a major challenge. We have shown TBN can efficiently deliver siRNA to cytoplasm of KRAS mutant H23 Non-Small Cell Lung Cancer (NSCLC) cells for oncogene knockdown; subsequently, sensitizing it to TKI...
August 17, 2016: Scientific Reports
https://read.qxmd.com/read/26839216/a-cross-species-study-of-pi3k-protein-protein-interactions-reveals-the-direct-interaction-of-p85-and-shp2
#8
Susanne B Breitkopf, Xuemei Yang, Michael J Begley, Meghana Kulkarni, Yu-Hsin Chiu, Alexa B Turke, Jessica Lauriol, Min Yuan, Jie Qi, Jeffrey A Engelman, Pengyu Hong, Maria I Kontaridis, Lewis C Cantley, Norbert Perrimon, John M Asara
Using a series of immunoprecipitation (IP)-tandem mass spectrometry (LC-MS/MS) experiments and reciprocal BLAST, we conducted a fly-human cross-species comparison of the phosphoinositide-3-kinase (PI3K) interactome in a drosophila S2R+ cell line and several NSCLC and human multiple myeloma cell lines to identify conserved interacting proteins to PI3K, a critical signaling regulator of the AKT pathway. Using H929 human cancer cells and drosophila S2R+ cells, our data revealed an unexpected direct binding of Corkscrew, the drosophila ortholog of the non-receptor protein tyrosine phosphatase type II (SHP2) to the Pi3k21B (p60) regulatory subunit of PI3K (p50/p85 human ortholog) but no association with Pi3k92e, the human ortholog of the p110 catalytic subunit...
February 3, 2016: Scientific Reports
https://read.qxmd.com/read/26056041/angptl2-lilrb2-signaling-promotes-the-propagation-of-lung-cancer-cells
#9
Xiaoye Liu, Xiaoting Yu, Jingjing Xie, Mengna Zhan, Zhuo Yu, Li Xie, Hongxiang Zeng, Feifei Zhang, Guoqiang Chen, Xianghua Yi, Junke Zheng
Immune inhibitory receptors expressed on various types of immune cells deliver inhibitory signals that maintain the homeostasis of the immune system. Recently we demonstrated that leukocyte immunoglobulin-like receptor subfamily B member 2 (LILRB2) and its murine homolog, paired immunoglobulin-like receptor B (PIRB), are expressed on hematopoietic stem cells and acute myeloid leukemia stem cells and function in maintenance of stemness. Herein, we determined that both LILRB2 and its soluble ligand ANGPTL2 are highly expressed in non-small cell lung cancer (NSCLC) samples, and levels are adversely related to patient prognosis...
August 28, 2015: Oncotarget
https://read.qxmd.com/read/25806289/predicting-resistance-by-selection-of-signaling-pathways
#10
REVIEW
Niki Karachaliou, Rafael Rosell, Miguel Angel Molina, Santiago Viteri
Epidermal growth factor receptor (EGFR) mutations occur in 17% of non-small-cell lung cancer (NSCLC) patients with notable response to single agent therapy but with low complete remission rate and, eventually, disease progression. Priming BIM, a pro-apoptotic signaling BH3-only protein, induces sensitivity to erlotinib in EGFR-mutant cell lines. Synthetic lethal approaches and preemptive therapies based on the initial expression of BIM may significantly improve the treatment outcome. EGFR mutations result in transient pro-death imbalance of survival and apoptotic signaling in response to EGFR inhibition...
April 2014: Translational Lung Cancer Research
https://read.qxmd.com/read/24041688/targeting-shp2-for-egfr-inhibitor-resistant-non-small-cell-lung-carcinoma
#11
Jie Xu, Li-Fan Zeng, Weihua Shen, John J Turchi, Zhong-Yin Zhang
Targeted therapy with inhibitors of epidermal growth factor receptor (EGFR) has produced a noticeable benefit to non-small cell lung cancer (NSCLC) patients whose tumors carry activating mutations (e.g. L858R) in EGFR. Unfortunately, these patients develop drug resistance after treatment, due to acquired secondary gatekeeper mutations in EGFR (e.g. T790M). Given the critical role of SHP2 in growth factor receptor signaling, we sought to determine whether targeting SHP2 could have therapeutic value for EGFR inhibitor resistant NSCLC...
October 4, 2013: Biochemical and Biophysical Research Communications
https://read.qxmd.com/read/23343958/expression-of-shp2-and-related-markers-in-non-small-cell-lung-cancer-a-tissue-microarray-study-of-80-cases
#12
Chunlan Tang, Dan Luo, Heping Yang, Qingliang Wang, Rong Zhang, Guoxiang Liu, Xiangdong Zhou
The purpose of this study was to assess the relationships between the expression of SHP2 and VEGF, VEGFR-1, VEGFR-2, MMP-2, MMP-9, TIMP-1, TIMP-2, and microvessel density (MVD), as well as the clinicopathologic parameters of these markers in non-small cell lung cancer (NSCLC). Using a tissue microarray, the expression of these 8 markers in 80 NSCLC cases was detected by immunohistochemistry. The expression of the markers was higher in cancer tissues when compared with the surrounding tissues. The MVD was lower in the CD34-positive cancer tissues than in the surrounding tissues...
October 2013: Applied Immunohistochemistry & Molecular Morphology: AIMM
https://read.qxmd.com/read/22777356/diminished-functional-role-and-altered-localization-of-shp2-in-non-small-cell-lung-cancer-cells-with-egfr-activating-mutations
#13
C M Furcht, A R Muñoz Rojas, D Nihalani, M J Lazzara
Non-small cell lung cancer (NSCLC) cells harboring activating mutations of the epidermal growth factor receptor (EGFR) tend to display elevated activity of several survival signaling pathways. Surprisingly, these mutations also correlate with reduced phosphorylation of ERK and SHP2, a protein tyrosine phosphatase required for complete ERK activation downstream of most receptor tyrosine kinases. As ERK activity influences cellular response to EGFR inhibition, altered SHP2 function could have a role in the striking response to gefitinib witnessed with EGFR mutation...
May 2, 2013: Oncogene
https://read.qxmd.com/read/20840817/-expression-and-clinical-significance-of-shp2-in-the-tumor-tissues-of-smokers-with-lung-cancer
#14
Xuemei Zhan, Hongyan Dong, Chongwei Sun, Lili Liu, Dan Wang, Zhiyong Wei
BACKGROUND AND OBJECTIVE: It has been proved that protein phosphorylation and dephosphorylation were important mechanisms in lung cancer development, and tobacco smoking is an important risk factor of lung cancer. The aim of this study is to investigate the expression and clinical significance of protein tyrosine phosphatase SHP2 in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC); the relationship between tobacco smoking and the expression of SHP2 is also studied...
September 2010: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
https://read.qxmd.com/read/20673499/-expression-and-its-clinical-significance-of-shp2-in-non-small-cell-lung-cancer
#15
Chunlan Tang, Xiangdong Zhou, Heping Yang, Qinglian Wang, Rong Zhang
BACKGROUND AND OBJECTIVE: Precious studies proven that aberrant tyrosine phosphorylation has linked with cancer. The aim of this work is to study the expression and significance of SHP2 in non-small cell lung cancer (NSCLC) through tissue microarray technique and immunohistochemical method. METHODS: Eighty NSCLC specimens were constructed into tissue microarray and performed using immunohistochemistry. RESULTS: The total positive rates of SHP2 were 70...
February 2010: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
https://read.qxmd.com/read/20406974/impaired-shp2-mediated-extracellular-signal-regulated-kinase-activation-contributes-to-gefitinib-sensitivity-of-lung-cancer-cells-with-epidermal-growth-factor-receptor-activating-mutations
#16
Matthew J Lazzara, Keara Lane, Richard Chan, Paul J Jasper, Michael B Yaffe, Peter K Sorger, Tyler Jacks, Benjamin G Neel, Douglas A Lauffenburger
Most non-small cell lung cancers (NSCLC) display elevated expression of epidermal growth factor receptor (EGFR), but response to EGFR kinase inhibitors is predominantly limited to NSCLC harboring EGFR-activating mutations. These mutations are associated with increased activity of survival pathways, including phosphatidylinositol 3-kinase/AKT and signal transducer and activator of transcription 3/5. We report that EGFR-activating mutations also surprisingly lead to decreased ability to activate extracellular signal-regulated kinase (ERK) compared with wild-type EGFR...
May 1, 2010: Cancer Research
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"